Unknown PHASE4 INTERVENTIONAL 1-arm NCT01380951

Safety and Efficacy of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B (CHB)

Clinical Study of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B

Sponsor: The Fifth People's Hospital of Suzhou

Conditions Chronic Hepatitis B Liver Cirrhosis

Interventions telbivudine

Updated 4 times since 2017 Last updated: Jun 23, 2011 Started: May 31, 2011 Primary completion: Dec 31, 2012 Completion: Dec 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Chronic Hepatitis B and Liver Cirrhosis and is currently ongoing. The Fifth People's Hospital of Suzhou leads this study, which shows 4 recorded versions since 2011 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE4
Jan 2017 — Jan 2021 [monthly]

Unknown Status PHASE4

First recorded

May 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

The Fifth People's Hospital of Suzhou

Data source: The Fifth People's Hospital of Suzhou

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Suzhou, China